05:04

Imugene (ASX:IMU) | JMM & éthica Capital Innovation Interview \ May 2024

15:06

Imugene (ASX:IMU) | JMM & éthica Capital Innovation & Investment Insights | May 2024

18:05

Investor webinar – Imugene Limited (ASX:IMU) & Kincell Bio Strategic Partnership Investor Webinar

06:20

MD & CEO Leslie Chong Discusses Bile Tract Cancer Study Expansion & Strategic Partnership

06:37

Leslie Chong Discusses Imugene's Strategic Partnership with Kincell Bio | AusBiz Interview

05:34

Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million

05:02

Imugene opens enrolment for Bile Tract Cancer expansion study

20:44

Imugene Limited: ASX Small and Mid Cap Conference March 2024

04:28

Imugene with Proactive at ASX Small and Mid Cap Conference

26:23

Imugene (ASX:IMU) Presentation, NWR Virtual Healthcare Conference

07:40

Imugene Limited (ASX: IMU) Emergence 2024: Presentation by Leslie Chong, Managing Director and CEO

03:04

Imugene progresses onCARlytics solid tumour trial to combination arm

04:30

Imugene Ltd MD and CEO shares with JustStocks plans for Phase 1 onCARlytics Combination Study

06:34

Imugene's Presentation at the Capital HQ MasterClass

04:28

Imugene Ltd CEO & Managing Director Leslie Chong speaks with JustStocks

05:00

Imugene doses first patient in intravenous monotherapy arm of Phase 1 clinical trial

02:18

7 News Australia | Australian company Imugene; saving lives using a cancer eating virus

19:03

Imugene steps up dosage at groundbreaking VAXINIA cancer trial

07:36

CEO Leslie Chong interview with Proactive Investors on Phase 1 MAST Results

14:29

Imugene Limited J.P. Morgan Healthcare Conference Presentation

04:15

Imugene Commences new PD1-Vaxx Bowel Cancer Trial

04:30

Imugene's CF33 VAXINIA Granted FDA Fast Track Designation

06:30

Azer-cel best in class Allogeneic CAR T cell therapy?

39:40

Imugene Investor Webinar with special guests Bradley Glover and Paul Woodard

27:13

Imugene Investor Webinar: MAST Study Update

04:45

Imugene News: Positive early signals show VAXINIA’s promise as a potent anti-cancer drug

02:30

Imugene thrilled as first patient dosed in Phase 1 OASIS trial

33:41

Imugene Investor Webinar | Acquisition of License for Azer-Cel Cell Therapy

00:34

Imugene Licenses Potential for First “Allo” CAR T to be Approved in Blood Cancer

04:00

First Patient dosed in Imugene's PD1-Vaxx Combination Trial

23:29

Imugene Investor Webinar | FDA IND Clearance for onCARlytics

04:52

'The Why' | Imugene, Developing Cancer Immunotherapies ASX: IMU

00:40

Meet Professor Yuman Fong, Imugene's Scientific Advisory Board Member

05:45

Dosing in cohort 3 of Imugene's VAXINIA monotherapy dose escalation trial

18:46

Investor Presentation: CEO Leslie Chong at the 2023 NWR Virtual Healthcare Conference

44:28

Imugene Investor Presentation | Non-deal Roadshow 2023 Australia

05:15

Imugene | First patients dosed in VAXINIA MAST combination study

04:25

Post JP Morgan Healthcare Conference interview with Proactive Investors

16:42

Imugene's CEO Leslie Chong presents at the 2023 JP Morgan Healthcare Conference in San Francisco.

07:10

Imugene CEO Leslie Chong speaks about the company's positive new data at the ESMO Asia Congress 2022

04:53

Imugene featured on Fox Business's 'Trending Today' as a trailblazer in the biotechnology industry.

04:50

Leslie Chong talks about Imugene's ABL partnership for VAXINIA

05:20

First patient in nextHERIZON Phase 2 clinical trial

04:45

First cohort 3 patient dosed in CHECKvacc trial

05:30

Imugene releases final data from Phase 2 HER Vaxx study

06:40

IMUGENE DOSES FIRST PATIENT IN VAXINIA PHASE 1 TRIAL

04:45

Imugene Receives Ethics Approval to Start Phase 2 Clinical Trial

32:59

Imugene's Science Series: PD1-Vaxx | B cell immunotherapy

00:37

Imugene's Science Series: PD1-Vaxx (intro)

06:29

Imugene finishes Phase 1a monotherapy dose escalation of PD1 Vaxx

04:45

Leslie Chong's first interview following our news Imugene secured two FDA IND approvals

04:12

Imugene's CEO interviewed on ausbiz detailing a clinical trial deal with Merck Germany and Pfizer.

05:39

Imugene Announces Clinical Trial Supply Agreement with Merck KGaA and Pfizer for HER-Vaxx

19:06

Imugene's Founder and Executive Chairman's keynote speech at Emerging Small Caps Summit 2021

30:02

Imugene's Science Series featuring the Oncolytic Viraltherapy CHECKvacc

18:08

ASX/ausbiz Biotech Unlocked with Imugene CEO Leslie Chong

00:36

Imugene's Science Series: CHECKvacc with Professor Yuman Fong and Dr. Yuan Yuan.

08:29

Imugene's Leslie Chong details Eureka Therapeutics collaboration

26:56

Investor Presentation post ASX news: Imugene and Eureka Therapeutics onCARlytics Collaboration

29:19

Imugene + Celularity Announce an Exclusive Strategic Partnership to Develop a Novel Oncolytic Virus.